Skip to content
The Intraday
Pulse TodayMorning BriefMid-Morning BriefMorning ReportMarket OverviewPre-MarketChartFundamentalsOverviewMarket InternalsFinancialsInternationalInsiders

Inovio Pharmaceuticals, Inc.

INO
$0.65
$-0.39 (-37.50%)
Open
Loading chart...
IndexN/A
Market Cap0.03B
Enterprise Value0.05B
Income$-0.02B
Sales$0.00B
EmployeesN/A
P/E-0.64
P/S1248.52
P/B3.39
P/C-0.92
EV/EBITDA-0.57
EV/SalesN/A
EPS (ttm)-1.02
EarningsN/A
Gross Margin100.00%
Oper. Margin-132871.32%
Profit Margin-130000.00%
Volume28.03M
Shs Outstand0.05B
Change-37.50%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Yesterday09:00PMINOVIO Announces Pricing of $20.0 Million Public Offering(gurufocus.com)08:53PMINOVIO Announces Pricing of $20.0 Million Public Offering(prnewswire.com)04:01PMINOVIO Announces Proposed Public Offering(prnewswire.com)
Jun 404:37PMKuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm(prnewswire.com)11:41AMInovio Pharmaceuticals, Inc. (INO) Presents at Jefferies Global Healthcare Conference 2026 Transcript(seekingalpha.com)
Jun 212:09PMKuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm(globenewswire.com)
Jun 105:24PMKuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm(newsfilecorp.com)
May 2808:05AMINOVIO to Participate in Upcoming Scientific and Investor Conferences(prnewswire.com)
May 2502:03PMInovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances(marketbeat.com)
May 2104:05PMPositive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China(prnewswire.com)
May 1409:55AMInovio: All Eyes On INO-3107 As Binary FDA Decision Looms(seekingalpha.com)
May 1309:30PMInovio Pharmaceuticals, Inc. (INO) Q1 2026 Earnings Call Transcript(seekingalpha.com)04:05PMINOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights(prnewswire.com)
May 1107:53AMHantavirus cases spark surge in pharma and biotech stocks — here's why(cnbc.com)
May 808:05AMINOVIO to Participate in Upcoming Scientific Conferences(prnewswire.com)
May 104:05PMINOVIO to Report First Quarter Financial Results on May 13, 2026(prnewswire.com)
Apr 2801:36PMVertex Gears Up to Report Q1 Earnings: What Investors Can Expect(zacks.com)
Apr 703:46PMPomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INO(globenewswire.com)02:52PMINO Deadline Today: INO Investors with Losses in Excess of $100K Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit(prnewswire.com)11:16AMInovio Deadline Today: Rosen Law Firm Urges Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights(businesswire.com)09:54AMINO CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026(businesswire.com)09:00AMINO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Inovio Pharmaceuticals, Inc. Securities Lawsuit -- The Gross Law Firm(prnewswire.com)
Apr 605:38PMBragar Eagel & Squire, P.C. Urgently Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before April 7th(globenewswire.com)04:12PMINOVIO DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - INO(newsfilecorp.com)12:00PMBronstein, Gewirtz & Grossman LLC Urges Inovio Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm(globenewswire.com)12:00PMDeadline Soon: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit(businesswire.com)10:50AMPortnoy Law Firm Announces Class Action on Behalf of Inovio Pharmaceuticals, Inc. Investors(globenewswire.com)09:42AMINO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026(newsfilecorp.com)09:30AMINO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm(globenewswire.com)03:46AMInovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO(prnewswire.com)

Insider Trading

No insider trades found for INO.

Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.

CEO: Jacqueline E. SheaEmployees: 112www.inovio.com
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Revenue$217.76K$832.01K$10.26M$1.77M$7.41M$4.11M$30.48M$42.22M
Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/A
Gross Profit$217.76K$832.01K$10.26M$1.77M$7.41M$4.11M$30.48M$42.22M
Gross Margin100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Expenses$112.62M$144.77M$277.84M$302.99M$131.49M$115.22M$124.57M$125.86M
Operating Income$-112.40M$-143.94M$-267.57M$-301.22M$-124.08M$-111.11M$-94.09M$-83.64M
Operating Margin-51616.91%-17300.28%-2607.35%-16972.34%-1674.25%-2702.10%-308.68%-198.11%
Net Income$-107.25M$-135.12M$-279.82M$-303.66M$-166.41M$-119.36M$-96.97M$-88.21M
Net Margin-49254.27%-16239.87%-2726.67%-17109.87%-2245.39%-2902.75%-318.12%-208.92%
EPS (Basic)$-3.95$-6.09$-14.07$-1.42$-1.07$-0.97$-1.05$-1.08
EBITDAN/AN/AN/AN/AN/AN/AN/AN/A
Stock Option Compensation ExpenseN/AN/AN/AN/AN/AN/AN/AN/A
Price To Earnings RatioN/AN/AN/AN/AN/AN/AN/AN/A
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market CapitalizationN/AN/AN/AN/AN/AN/AN/AN/A

Discover more

You may be interested in
AMD

Advanced Micro Devices

$488.58

↑ 13.74%
ABX

Abacus Global Management Inc

$10.38

↑ 0.83%
ORCL

Oracle Corp

$126.35

↑ 7.31%
IBM

IBM Corp

$221.68

↓ 2.10%
BAC

Bank of America Corp

$61.72

↑ 1.06%
V

Visa Inc

$363.65

↓ 1.38%
NFLX

Netflix Inc

$73.09

↓ 0.73%
PYPL

PayPal Holdings Inc

$57.34

↓ 1.72%
GOOGL

Alphabet Inc

$332.67

↓ 1.20%
AMZN

Amazon.com Inc

$237.28

↑ 4.69%
MSFT

Microsoft Corp

$457.89

↑ 17.25%
META

Meta Platforms Inc

$533.15

↓ 8.96%
The Intraday

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC